VivoSeq
Oncology

Leukemia

426

Pipeline Programs↗

86

Active Trials↗

116

Companies Involved↗

Leukemia is a highly competitive landscape with 426 programs across 116 companies. The most active players are Kymera Therapeutics, Inc., Vion Pharmaceuticals, Hrain Biotechnology Co., Ltd.. 30 therapies are approved with 63 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

92/100

Pipeline Velocity

41/100

Mech. Concentration

5/100

Completion Rate

71/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Kymera Therapeutics, Inc.

2 programs

Phase 1V

Vion Pharmaceuticals

1 program

Phase 1H

Hrain Biotechnology Co., Ltd.

1 program

Phase 1K

Kecellitics Biotech Company Ltd

1 program

Phase 1C

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

1 program

Phase 1C

Cyclacel Pharmaceuticals, Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical20

Furosemide

Validus Pharmaceuticals

Dexamethasone Sodium Phosphate

Quince Therapeutics S.p.A.

Rasburicase

Azienda U.S.L. 1 di Massa e Carrara

Methylprednisolone Sodium Succinate

Massachusetts Eye and Ear Infirmary

Interferon Alpha

Ainos, Inc. (f/k/a Amarillo Biosciences Inc.

Phase 1134

Nilotinib

Azurity Pharmaceuticals

Tocilizumab

Roche

Nivolumab

Bristol-Myers Squibb

Mitoxantrone

EMD Serono

Pravastatin

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2179

Dasatinib

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Revumenib

Syndax Pharmaceuticals

Tipifarnib

Kura Oncology, Inc.

Ponatinib

Takeda

Blinatumomab

Amgen

Phase 363

Asparaginase

Dutch Childhood Oncology Group

Alemtuzumab

Genzyme, a Sanofi Company

Aldesleukin

Iovance Biotherapeutics, Inc.

Epoetin Alfa

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Gemtuzumab Ozogamicin

Wyeth-Lederle Vaccines

Approved30

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Binimetinib

Pfizer

Propofol

Fresenius Kabi Oncology Ltd.

Docetaxel

Avyxa

Adenosine

Astellas

Analysis

Modality Breakdown

77%

Small molecule

340 of 439 classified programs — the dominant modality here.

23%ALL OTHERSCell therapy5412%Monoclonal antibody215%Protein / enzyme184%Antibody–drug conjugate3<1%Vaccine2<1%Gene therapy1<1%

Small molecule leads; the ring shows all 439 classified programs, each share of the total. Modality classified for 99% of 509 pipeline programs.

Analysis

Trial Status

479

clinical trials

Completed232 · 48%
Terminated72 · 15%
Unknown status64 · 13%
Recruiting50 · 10%
Active, not recruiting24 · 5%
Withdrawn23 · 5%
Other14 · 3%

Clinical Trials

Trial Activity

479 trials

JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
Recruiting·TTongji Hospital·N/A·NCT06689917·20 enrolled
Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia
Recruiting·YYonsei University·Phase 2·NCT06516679·40 enrolled
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05645718·27 enrolled
Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia
Recruiting·—·Phase 2·NCT07321301·10 enrolled
JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
Recruiting·SShenzhen Genocury Biotech Co., Ltd.·N/A·NCT06890065·20 enrolled
Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia
Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 2/3·NCT06607419·90 enrolled
Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
Recruiting·—·Phase 2·NCT05592015·30 enrolled
Pilot Imaging Study of Leukemia
Recruiting·UUniversity of Oklahoma·Phase 1·NCT03633955·60 enrolled
CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia
Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT06847269·25 enrolled
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT07011004·18 enrolled
Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS
Recruiting·—·Phase 2·NCT04741945·40 enrolled
Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
Recruiting·ZZhejiang University·Phase 1·NCT07429461·16 enrolled
Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT04881240·60 enrolled
CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
Recruiting·ZZhujiang Hospital·Phase 1·NCT03291444·30 enrolled
Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention
Recruiting·AAzienda Ospedaliero-Universitaria di Parma·N/A·NCT06626893·100 enrolled
Page 1 of 32

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)